Targeting the MYC Oncogene with CDK Inhibitors

使用 CDK 抑制剂靶向 MYC 癌基因

• 批准号: 8063614
• 负责人: ANDREI GOGA
• 金额: $ 36.69万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-19 至 2015-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8063614
• 关键词: Acute; Address; Alleles; Apoptosis; Apoptotic; Automobile Driving; BCL2 gene; BCL2L11 gene; BIM Bcl-2-binding protein; BIRC5 gene; Biological; CDC2 Protein Kinase; CDK2 gene; Cell Cycle; Cell Cycle Inhibition; Cell Death; Cell Proliferation; Cell Survival; Cell physiology; Cells; Cessation of life; Clinical Trials; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor; Cyclin-Dependent Kinases; Development; Down-Regulation; Enzymes; Eukaryotic Cell; Event; Family; Family member; Genetic; Genetic Transcription; Goals; Human; Individual; Investigation; Knowledge; Lead; Lymphoma; Malignant Neoplasms; Malignant neoplasm of liver; Mammalian Cell; Mammary Neoplasms; Mediating; MicroRNAs; Mitotic; Mitotic spindle; Modeling; Molecular; Molecular Target; Mus; Mutation; Normal Cell; Normal tissue morphology; Oncogenes; Oncogenic; Pathway interactions; Phase; Phosphorylation; Phosphotransferases; Play; Proliferating; Protein Kinase; Proteins; Regulation; Role; Series; Site; Specificity; Testing; Therapeutic; Time; Transgenic Mice; Translations; Up-Regulation; Work; analog; attenuation; base; cancer cell; cancer therapy; cell killing; cellular engineering; chemical genetics; clinical practice; improved; in vivo; inhibitor/antagonist; innovation; killings; malignant breast neoplasm; mouse model; neoplastic; neoplastic cell; new therapeutic target; novel; novel therapeutics; overexpression; prevent; programs; public health relevance; receptor; small molecule; survivin; synthetic biology; therapeutic target; transcription factor; tumor

DESCRIPTION (provided by applicant): The promise of molecular targeted therapy for cancer is to provide selective killing of tumor cells while sparing normal cells. Targeted therapy, however, requires that the oncogenic pathways activated in tumor cells can be defined, and that selective inhibitors can be found to abrogate these pathways. One major limitation to targeted therapeutic approaches is that many oncogenic pathways, especially those involving transcription factors, cannot be directly inhibited with small molecule compounds. An alternative approach is to use small molecule inhibitors that target basic cellular processes, such as the cell cycle, which merely arrest normal cells, but which in combination with activation of particular oncogenic pathways result in synthetic-lethal combinations. Cyclin-dependent kinases (CDKs) are a conserved family of protein kinases that play a central role in regulating the eukaryotic cell cycle. CDK1 and CDK2 are thought to be particularly important for driving the major cell cycle events in normal and neoplastic mammalian cells and these kinases might therefore be important targets for cancer therapy. The overall hypothesis that is being tested is whether inhibition of different CDKs can result in selective killing of tumor versus normal cells. (1) We seek to determine the genetic context in which cells are rendered especially sensitive to CDK inhibitors, resulting in cell death or another abortive cell cycle program. (2) We seek to determine how MYC oncogene over- expression sensitizes to cell death following CDK1 inhibition. (3) We seek to understand the molecular basis for cell death induced by CDK inhibition. To accomplish our goals we will utilize two complementary approaches to address this question. Both conventional small-molecule CDK inhibitors as well as a chemical-genetic approach will be employed to identify the genetic context in which CDK inhibitors may prove to be useful therapeutics. Our hypothesis, if confirmed, will significantly improve our understanding of how CDK inhibitors may be useful to target specific oncogenic pathways and should lead to novel therapeutics for cancer. PUBLIC HEALTH RELEVANCE: Normal cellular proliferation requires an orderly progression through the cell cycle that involves multiple regulatory enzymes. In contrast, cancer cells proliferate inappropriately and without end resulting in a tumor mass. Since tumor cells proliferate inappropriately, precise inhibition of the cell cycle may lead to the death of tumor cells while normal cells may be spared. The goal of this proposal is to determine if selective inhibition of cell cycle regulatory enzymes, known as cyclin-dependent kinases (CDKs), can cause the arrest or perhaps death of tumor cells. The knowledge gained from these studies will facilitate the development of new therapeutics that target tumor cells with particular genetic changes by precisely inhibiting the cell division cycle.

描述（由申请人提供）：分子靶向治疗癌症的前景是在保留正常细胞的同时选择性地杀死肿瘤细胞。然而，靶向治疗需要确定肿瘤细胞中激活的致癌途径，并找到选择性抑制剂来消除这些途径。靶向治疗方法的一个主要限制是许多致癌途径，特别是那些涉及转录因子的途径，不能用小分子化合物直接抑制。另一种方法是使用针对基本细胞过程（如细胞周期）的小分子抑制剂，这种抑制剂只会抑制正常细胞，但与特定致癌途径的激活结合会产生合成致死组合。细胞周期蛋白依赖性激酶（CDKs）是一个保守的蛋白激酶家族，在调节真核细胞周期中起核心作用。CDK1和CDK2被认为对于驱动正常和肿瘤哺乳动物细胞的主要细胞周期事件特别重要，因此这些激酶可能是癌症治疗的重要靶点。正在测试的总体假设是，抑制不同的CDKs是否会导致选择性杀死肿瘤细胞而不是正常细胞。(1)我们试图确定细胞对CDK抑制剂特别敏感的遗传背景，从而导致细胞死亡或另一个流产的细胞周期程序。(2)我们试图确定MYC癌基因的过表达如何在CDK1抑制后对细胞死亡敏感。(3)我们试图了解CDK抑制诱导细胞死亡的分子基础。为了实现我们的目标，我们将利用两种互补的方法来解决这个问题。传统的小分子CDK抑制剂以及化学遗传学方法都将被用来确定CDK抑制剂可能被证明是有用的治疗方法的遗传背景。我们的假设，如果得到证实，将显著提高我们对CDK抑制剂如何有效靶向特定致癌途径的理解，并可能导致癌症的新疗法。